Aeglea Biotherapeutics Inc (AGLE) Has a New Rating from H.C. Wainwright

By Austin Angelo

In a report released today, Edward White from H.C. Wainwright initiated coverage with a Buy rating on Aeglea Biotherapeutics Inc (AGLEResearch Report) and a price target of $20. The company’s shares closed yesterday at $6.50, close to its 52-week low of $6.31.

White wrote:

“We base our $20 price target on probability-adjusted revenue forecasts for pegzilarginase in ARG1-D and our year end fully diluted net cash estimate of $2.55/share to arrive at our price target. We use the net present value of our revenue forecast through 2028, apply a 50% POS of pegzilarginase in 4x price/sales multiple for ARG1-D to arrive at a value of $4.40/share. We use a 20% discount rate for the NPV of the pipeline as it is within the typical range of 15-25% for products in development. Our P/S multiple of 4x is in line with Aeglea’s peers at approximately 2-5x.”

According to TipRanks.com, White is a 5-star analyst with an average return of 14.4% and a 47.0% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Aileron Therapeutics Inc.

Currently, the analyst consensus on Aeglea Biotherapeutics Inc is a Moderate Buy with an average price target of $17.

See today’s analyst top recommended stocks >>

Based on Aeglea Biotherapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $17.17 million. In comparison, last year the company had a GAAP net loss of $8.12 million.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGLE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.